These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11333516)

  • 1. [Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].
    Sacristán JA; Gómez JC; Ferre F; Gascón J; Pérez Bravo A; Olivares JM
    Actas Esp Psiquiatr; 2001; 29(1):25-32. PubMed ID: 11333516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
    Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
    Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
    Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
    Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
    Crawford AM; Beasley CM; Tollefson GD
    Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Ann Pharmacother; 2001 Dec; 35(12):1517-22. PubMed ID: 11793611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).
    García-Cabeza I; Gómez JC; Sacristán JA; Edgell E; González de Chavez M
    BMC Psychiatry; 2001; 1():7. PubMed ID: 11835695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
    Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
    Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
    Bobes J; Gibert J; Ciudad A; Alvarez E; Cañas F; Carrasco JL; Gascón J; Gómez JC; Gutiérrez M
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):473-81. PubMed ID: 12691783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
    J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
    Gómez JC; Sacristán JA; Hernández J; Breier A; Ruiz Carrasco P; Antón Saiz C; Fontova Carbonell E
    J Clin Psychiatry; 2000 May; 61(5):335-43. PubMed ID: 10847307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
    Inada T; Beasley CM; Tanaka Y; Walker DJ
    Int Clin Psychopharmacol; 2003 Jan; 18(1):39-48. PubMed ID: 12490774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
    Purdon SE; Woodward N; Lindborg SR; Stip E
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):390-7. PubMed ID: 12827347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
    Tollefson GD; Sanger TM; Beasley CM; Tran PV
    Biol Psychiatry; 1998 Jun; 43(11):803-10. PubMed ID: 9611669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
    Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
    Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.